HarmoniaMentisHarmoniaMentis

Resources

  1. Home
  2. Welcome to HarmoniaMentis

  3. You are here: Resources

Welcome to the Resources vault for ONTOZRY®▼ (cenobamate)

A comprehensive library of resources designed to support your clinical practice and patients prescribed ONTOZRY®. All resources are available in print and digital versions. To order print copies, please email info@angelinipharma.com.

For healthcare professionals - Resources designed for your clinical practice

For patients – Resources designed for your patients prescribed ONTOZRY®

Indications

United Kingdom: ONTOZRY® (cenobamate) is indicated for the adjunctive treatment of focal–onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite treatment with at least 2 anti–epileptic medicinal products.1

Republic of Ireland: ONTOZRY® (cenobamate) is indicated for the adjunctive treatment of focal–onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti–epileptic medicinal products.1

  1. ONTOZRY® Summary of Product Characteristics. United Kingdom and European Union.

MAT-UKI-0455-P | June 2026